SMC Backs First-Line Metastatic Bladder Cancer Combination After Trial Results

Why It Matters

The endorsement gives NHS Scotland patients access to a regimen that more than doubles survival, reshaping first‑line care for advanced bladder cancer and setting a new standard across the UK.

Key Takeaways

• Enfortumab vedotin + pembrolizumab doubles median overall survival
• Median OS 33.8 months vs 15.9 months for chemo
• Complete response rate 30.4% versus 14.5% with chemo
• SMC reimbursement enables NHS Scotland access to combo therapy
• First‑line bladder cancer treatment unchanged since 1980s now revamped

Pulse Analysis

Bladder cancer remains a leading cause of cancer mortality in the United Kingdom, with roughly 200 Scottish patients diagnosed each year with unresectable or metastatic disease. Historically, clinicians relied on platinum‑based chemotherapy or single‑agent immunotherapy, both offering modest benefits and median survival under two years. The introduction of antibody‑drug conjugates such as enfortumab vedotin, paired with checkpoint inhibition, represents a paradigm shift that addresses the unmet need for durable responses in a population where 71% of stage IV patients die within a year.

The EV‑302 phase 3 trial provided robust evidence that the enfortumab‑pembrolizumab duo outperforms conventional chemotherapy. Patients receiving the combination achieved a median overall survival of 33.8 months—more than double the 15.9‑month benchmark—and a median progression‑free survival of 12.5 months, cutting the risk of disease progression by 55%. Moreover, a complete response was observed in 30.4% of participants, compared with just 14.5% under chemotherapy. These outcomes not only extend life expectancy but also improve quality of life by reducing treatment‑related toxicity, positioning the regimen as a new standard of care for first‑line therapy.

The SMC’s reimbursement decision translates clinical breakthroughs into real‑world access, ensuring that NHS Scotland patients can benefit from the same regimen already approved by the FDA and the European Commission. For Astellas, the endorsement unlocks a sizable market in the UK and reinforces its leadership in oncology innovation. The move also pressures other health systems to reassess legacy treatment pathways, potentially accelerating broader adoption of antibody‑drug conjugate strategies across Europe and North America. As data mature, the combination may become a benchmark for future trials targeting other aggressive urothelial cancers.